Actively Recruiting
Long-Term Safety Study of Oral Pirtobrutinib and Idelalisib in Patients With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Led by Eli Lilly and Company · Updated on 2026-11-04
150
Participants Needed
50
Research Sites
135 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the long-term safety of pirtobrutinib in people who have previously been treated for chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL. This study welcomes participants who completed the earlier LOXO-BTK-20020 trial to continue receiving the study drug or attend follow-up visits. The study is a Phase 4 treatment trial sponsored by Eli Lilly and Company. Participants will receive pirtobrutinib orally every 4 weeks. There is also a group receiving idelalisib orally. This study is designed as a parallel, non-randomized trial and is expected to last approximately 5 years, allowing continued access to treatment or follow-up for participants from the previous study. During the study, participants will be monitored for treatment-emergent adverse events of grade 3 or higher from the first dose through 30 days after the last dose or start of new anticancer therapy. Researchers will also track overall survival from enrollment in the original study until death from any cause, up to about 93 months. Participants will have regular visits over the study period for safety and health assessments.
CONDITIONS
Brief Title
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Research Team
T
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
P
Physicians interested in becoming principal investigators please contact
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here